Rentschler Biotechnologie, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, has announced the opening of a new single-use bioreactor at the company’s site in Laupheim with a capacity of 2000 L.
Rentschler continues to expand its cGMP manufacturing capacity only a few weeks after putting into operation an innovative twin system with two 3000 L stainless steel bioreactors.
In combination with its first 2000 L single-use bioreactor put into operation in 2015, Rentschler now has two 1000 L and two 2000 L single-use manufacturing systems available. This enables the complete manufacturing of recombinant proteins in single-use bioreactors, also for late stage clinical development and market supply of biopharmaceuticals for the treatment of severe illnesses.
“Only a few weeks after putting into operation our twin system, Rentschler is expanding its manufacturing capacity again with this new 2000L single-use bioreactor. This capacity expansion will enable us to meet the continuous growth in international business,” Dr Frank Mathias, Chief Executive Officer of Rentschler Biotechnologie GmbH, commented.
With its full-service concept, Rentschler offers targeted and client-specific solutions that meet highly diverse requirements in terms of scale, manufacturing volumes, and manufacturing characteristics and therefore maximize the efficiency and suitability of biopharmaceutical manufacturing.
“In the future, providing both single-use and stainless steel technologies will continue to play an important role and enable greater flexibility – also for our clients. We’re aligning our goals with our clients’ objectives,” Dr Frank Mathias added.
In the course of the continuous capacity expansion and investments at the company’s site in Laupheim, Rentschler is still looking to hire a variety of skilled employees, including process engineers and laboratory technicians in bioprocess development and manufacturing, as well as GMP (Good Manufacturing Practice) experts.
About single-use: Within a few years, single-use systems have led to a paradigm shift in the manufacturing of clinical test materials. Compared with stainless steel bioreactors, single-use systems not only carry a lower contamination risk, but are more cost-effective and can be implemented more quickly.
Of particular note is the flexibility offered by single-use systems, as manufacturing processes can be designed modularly and thus easily scaled. In addition, faster product changeover is possible, which enables reduced time-to-market. The two 2000 L single-use bioreactors can be run in parallel, thus providing higher throughput while reducing costs.